Particle.news
Download on the App Store
4 ARTICLES
·
4w ago

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

Phase 3 results show nearly 8% weight loss with tolerable side effects, setting the stage for a late-2025 obesity drug application

Image
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. REUTERS/Brendan McDermid/File Photo
The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid/File Photo

Overview

  • The 36 mg dose of orforglipron yielded an average 7.9% body weight reduction and lowered HbA1c by up to 1.6% over 40 weeks, matching semaglutide and tirzepatide injectables.
  • Daily dosing without food or water restrictions led all three tested doses to achieve significant blood sugar control in a 559-patient type 2 diabetes trial.
  • Gastrointestinal issues including diarrhea, nausea and indigestion were comparable to existing GLP-1 treatments, prompting 4–8% of participants to discontinue due to side effects.
  • Lilly plans to submit Phase 3 data for non-diabetic obesity patients in Q3 2025 and to file for weight management approval by year-end, followed by a type 2 diabetes application in 2026.
  • As an oral alternative that avoids cold-chain storage and injection requirements, orforglipron could expand global access and alleviate supply constraints for GLP-1 therapies.